Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success

开发、展示和传播创新项目以实现转化成功

• 批准号: 10413256
• 负责人: Barry Coller
• 金额: $ 368.16万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-05 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10413256
• 关键词: Address; Affect; Area; Bioethics; Biotechnology; Certification; Cessation of life; Clinical; Clinical Investigator; Clinical Nursing Research; Clinical Research; Clinical Sciences; Collaborations; Communities; Competence; Complex; Consultations; DNA sequencing; Data; Development; Diagnosis; Disease; Education; Elderly; Elements; Enrollment; Ensure; Environment; Evaluation; Formulation; Funding; Genome; Grant; Health; Health Policy; Hospitals; Human; Human Resources; Immunocompetence; Individual; Informed Consent; Infrastructure; Institutes; Institution; Knowledge; Laboratories; Leadership; Medical; Medicine; Methods; Modeling; Modification; Monitor; NCI Scholars Program; Neighborhood Health Center; New York; Nurses; Nursing Research; Outcome; Participant; Patients; Pennsylvania; Pharmacy facility; Phase; Policies; Population; Prevention; Public Health; Publications; Reporting; Reproducibility; Research; Research Design; Research Personnel; Resources; Science; Scientist; Special Population; Speed; Surveys; Time; Training; Translational Research; Translations; Universities; Vision; base; career; clinical center; clinical investigation; community engagement; design; experience; high standard; human disease; improved; innovation; monoclonal antibody production; multidisciplinary; next generation; novel; novel therapeutics; outreach; participant enrollment; participant safety; pharmacokinetics and pharmacodynamics; practice-based research network; programs; recruit; skills; success; therapeutic development; translational scientist

The overall vision of the Rockefeller University Center for Clinical and Translational Science (CCTS), supported by the CTSA program, is to develop, demonstrate, and disseminate innovative programs so as to create a model clinical research enterprise built on rigor, responsible and transparent reporting, and scientific integrity to empower translation of paradigm-breaking discoveries into better human health. Our new initiatives are designed to: 1) ensure that all of our studies set the highest standards; 2) ensure that our trainees have the team science leadership skills needed for a career in translational science; and 3) enhance scientific rigor, reproducibility, and reporting. These new areas build on the infrastructure we have developed to integrate mechanistic science into community engagement, reach out to basic scientists, speed the development of health- enhancing products, and create an optimal training environment. Our specific aims are: 1. To provide a robust infrastructure to support the conduct of clinical investigation at the highest levels of participant safety, scientific rigor, bioethics, and regulatory compliance. We will enhance our multidisciplinary Translational Research Navigation (TRN) Program and our collaboration with Clinical Directors Network (CDN), a Practice Based Research Network of Community Health Centers, to ensure that our studies meet the highest standards of design, feasibility, method validity, and transparent reporting, supporting our active participation in the CTSA Trial Innovation Network. 2. To ensure that every discovery at Rockefeller has the best chance of improving human health. We will enhance our robust pipeline of programs to support basic and clinical investigators move their paradigm-breaking discoveries into new therapeutics by leveraging the resources of the Tri-Institutional Therapeutic Development Institute, the Robertson Therapeutic Development Fund, and the University affiliated biotechnology company, Bridge Medicines .3. To educate the entire research workforce team in conducting translational research at the highest levels of participant safety, scientific rigor, bioethics, and regulatory compliance. We will further enhance the multidisciplinary team science emphasis of our educational programs for KL2 Clinical Scholars, Clinical Research Nurses, basic scientists, and community clinicians, with a focus on our new Team Science Leadership training with the CTSA Hubs at Yale, University of Pennsylvania, and Columbia. 4. To study and improve the clinical research enterprise both at Rockefeller and nationally. We will continue to use the CCTS as a laboratory for investigating the clinical research enterprise itself and methods to improve it, including obtaining outcome data from research participants, enhancing rigor, reproducibility and reporting, speeding the evaluation of novel therapeutics via in-house formulation, and creating 'super teams' of CTSA Hubs to disseminate our model of community engagement harnessing basic mechanistic studies to address community-identified health needs. We will disseminate the results throughout the CTSA consortium and scientific community by publications, presentations, and active participation in CLIC and CD2H initiatives.

洛克菲勒大学临床与翻译中心的整体愿景 CTSA计划支持的科学（CCT）是开发，证明和传播 创新计划以创建建立在严格的基础上的模型临床研究企业， 负责和透明的报告以及科学完整性，以增强 破坏范式的发现是更好的人类健康。我们的新计划旨在：1） 确保我们所有的研究都设定了最高标准； 2）确保我们的学员有团队 转化科学职业所需的科学领导能力； 3）增强 科学严谨，可重复性和报告。这些新领域以 我们已经开发了基础设施，以将机械科学整合到社区参与中， 与基本科学家接触，加快增强健康产品的发展，并创建 最佳培训环境。我们的具体目的是：1。为 支持最高参与者安全的临床研究的进行， 科学严谨，生物伦理学和法规合规性。我们将增强我们的多学科 翻译研究导航（TRN）计划以及我们与临床主管的合作 网络（CDN）是一个基于实践的社区卫生中心的研究网络，以确保我们的 研究符合设计的最高标准，可行性，方法有效性和透明度 报告，支持我们积极参与CTSA试验创新网络。 2。确保 洛克菲勒的每一个发现都有改善人类健康的最佳机会。我们将增强 我们支持基本和临床调查人员的计划的强大管道，将其移动 通过利用利用的资源，破坏范式的发现为新的治疗剂 罗伯逊治疗发展基金会三机构治疗发展研究所 和大学附属生物技术公司，桥梁药物.3。教育整个 研究劳动力团队在最高参与者进行翻译研究中 安全，科学严谨，生物伦理学和法规合规性。我们将进一步增强 我们针对KL2临床学者的教育计划的多学科团队科学强调， 临床研究护士，基础科学家和社区临床医生，重点是我们的新 团队科学领导力培训在耶鲁大学的CTSA枢纽，大学 宾夕法尼亚州和哥伦比亚。 4。研究和改善临床研究企业 洛克菲勒和全国。我们将继续使用CCT作为研究 临床研究企业本身和改善它的方法，包括获得结果数据 从研究参与者提高严格，可重复性和报告，加快评估 通过内部配方进行新颖的治疗方法，并创建CTSA枢纽的“超级团队” 传播我们的社区参与模型，利用基本的机械研究 满足社区确定的健康需求。我们将在整个CTSA中传播结果 通过出版物，演讲和积极参与的财团和科学界 CLIC和CD2H计划。